11 recruiting, 8 completed, 5 not yet recruiting, 3 active not recruiting. 33 Phase 4.
| Phase | Trials | Status |
|---|---|---|
| Phase 4 | 33 | Recruiting 11, Completed 8, Not yet recruiting 5, Active not recruiting 3, Withdrawn 3, Terminated 2, Enrolling by invitation 1 |
Follow Opioid Use Disorder: new trials by email Literature Review of Opioid Use Disorder trials Research Report on Opioid Use Disorder
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Examining Analgesic Synergy and Efficacy in Trauma Care Buprenorphine, Oxycodone - Opioid Use Disorder | Phase 4 | Not yet recruiting | Wake Forest University Health Sciences | 282 | 2027-03-01 | 2026-10-28 |
| Acceptability and Feasibility of Extended-Release Subcutaneous Buprenorphine on a Mobile Pharmacy Clinic Buprenorphine - Opioid Use Disorder | Phase 4 | Recruiting | Yale University | 60 | 2026-09-23 | 2026-10-09 |
| A Bundled Intervention to End Opioid Overdoses Bundled intervention (Experimental), control group, Buprenorphine (Experimental) - Opioid Use Disorder, Opioid Overdose | Phase 4 | Recruiting | University of Alabama at Birmingham | 160 | 2026-09-07 | 2026-10-02 |
| NOTRE: Optimizing Long-Acting Pre-Exposure Prophylaxis and Medications for Opioid Use Disorder Interventions in Carceral Settings Cabotegravir Injection, Cabotegravir Pill, Buprenorphine injection - HIV Infections, Opioid Use Disorder | Phase 4 | Not yet recruiting | Duke University | 450 | 2026-09-01 | 2026-08-26 |
| Comparing Outpatient Treatment Retention Among Individuals Using Fentanyl Randomized to Low-dose and Direct-to-inject Buprenorphine Initiation Injectable buprenorphine, Sublingual Buprenorphine (SUBOXONE, Zubsolv, or generic tablets) - Opioid Use Disorder, Fentanyl | Phase 4 | Not yet recruiting | University of California, San Francisco | 50 | 2026-06-01 | 2026-03-13 |
| Methadone Rapid Restart Methadone - Opioid Use Disorder | Phase 4 | Not yet recruiting | Pouya Azar | 25 | 2026-05-01 | 2026-04-22 |
| Symptom-Inhibited Naloxone Induction (SINI) for Buprenorphine Initiation: A Feasibility Trial Naloxone Hydrochloride 0.4 MG/ML, Buprenorphine hydrochloride and naloxone hydrochloride dihydrate sublingual tablet (2 mg/0.5 mg and 8 mg/2 mg), Buprenorphine extended-release injection (300 mg/1.5 mL) - Opioid Use Disorder | Phase 4 | Recruiting | Pouya Azar | 12 | 2026-04-29 | 2026-05-01 |
| Injectable Buprenorphine in Prison: A Preference Trial Brixadi (Injectable Buprenorphine), Sublocade - Opioid Use Disorder, Incarceration | Phase 4 | Recruiting | Lifespan | 60 | 2026-02-18 | 2026-05-15 |
| Intrathecal Hydromorphone vs Intrathecal Morphine to Treat Post Cesarean Pain in Patients With Opioid Use Disorder Taking Buprenorphine Morphine, Bupivacaine, Fentanyl - Opioid Use Disorder | Phase 4 | Withdrawn | University of North Carolina, Chapel Hill | 2026-02-01 | 2026-03-09 | |
| Assessing Optimal XRB Initiation Points in Jail Extended-Release Buprenorphine (XRB), Sublingual Buprenorphine (SLB) - Opioid Use Disorder | Phase 4 | Recruiting | NYU Langone Health | 50 | 2025-06-02 | 2026-08-07 |
| Buprenorphine as a Post-operative Analgesic in Opioid-Naive Patients After Ankle Fracture Surgery Buprenorphine Transdermal System, Placebo Patch - Pain, Postoperative, Ankle Fracture Surgery | Phase 4 | Recruiting | Jenna-Leigh Wilson | 100 | 2025-04-21 | 2026-04-06 |
| A Bundled Intervention a bundled intervention, including peer support specialist, buprenorphine, physician care, and telehealth - Opioid Use Disorder, Opioid Overdose | Phase 4 | Completed | University of Alabama at Birmingham | 30 | 2025-02-13 | 2026-10-28 |
| Low-dose Buprenorphine Initiation for Opioid Use Disorder buprenorphine-naloxone - Opioid Use Disorder | Phase 4 | Recruiting | Montefiore Medical Center | 70 | 2024-11-11 | 2026-07-21 |
| Evaluation of Switch to Dolutegravir/Lamivudine (DTG/3TC) From Current Suppressive Antiretroviral Therapy in People Living With HIV (PLWH) Receiving Opioid Agonist Therapy (OAT) DOVATO - HIV-1-infection, Opioid Use Disorder | Phase 4 | Not yet recruiting | Saskatchewan Health Authority - Regina Area | 40 | 2024-09-30 | 2024-08-30 |
| Low-dose Versus a High-dose Sublingual Buprenorphine Induction buprenorphine/naloxone - Opioid Use Disorder | Phase 4 | Active not recruiting | Friends Research Institute, Inc. | 40 | 2024-06-20 | 2025-08-12 |
| Office-based Methadone Versus Buprenorphine to Address Retention in Medication for Opioid Use Disorder Treatment. Methadone, Buprenorphine (BUP) - Opioid Use Disorder | Phase 4 | Recruiting | Yale University | 600 | 2024-06-04 | 2026-09-14 |
| Pain Self-Management and Patient-Oriented Dosing for Pain and in Retention Opioid Treatment Patient-Oriented Dosing (POD), Pain Self-Management (PSM), Usual Care - Opioid Use Disorder, Chronic Pain | Phase 4 | Active not recruiting | Erin Winstanley | 273 | 2024-05-28 | 2026-08-18 |
| Symptom-inhibited Fentanyl Induction Fentanyl, Methadone, Slow-release oral morphine - Opioid Use Disorder | Phase 4 | Completed | Pouya Azar | 48 | 2024-01-29 | 2026-03-16 |
| Assessing Optimal XR-Buprenorphine Initiation Points in Jail Extended-Release Buprenorphine Injection - Opioid Use Disorder | Phase 4 | Withdrawn | NYU Langone Health | 2023-11-01 | 2024-02-29 | |
| Integrated e-Health (Electronic Health) for HIV and Substance Use Disorders in Justice Involved Women Decision Aid, Athena strategy - HIV, Opioid Use Disorder | Phase 4 | Recruiting | Yale University | 250 | 2023-07-25 | 2026-06-03 |
Showing 20 of 33. Sign in to see all of them.
Opioid-Related Disorders (33) · Chronic Pain (2) · Emergencies (2) · HIV Infections (2) · Opiate Overdose (2) · Pain, Postoperative (2) · Acquired Immunodeficiency Syndrome (1) · Acute Pain (1) · Agnosia (1) · Ankle Fractures (1) · Back Pain (1) · Cognitive Dysfunction (1) · Pain (1) · Patient Participation (1) · Patient Satisfaction (1)
Chemically-Induced Disorders (33) · Mental Disorders (33) · Narcotic-Related Disorders (33) · Substance-Related Disorders (33) · Pathological Conditions, Signs and Symptoms (8) · Neurologic Manifestations (6) · Signs and Symptoms (6) · Pain (5) · Infections (4) · Pathologic Processes (4) · Blood-Borne Infections (3) · Communicable Diseases (3) · Genital Diseases (3) · Immune System Diseases (3) · Immunologic Deficiency Syndromes (3)
Buprenorphine, Naloxone Drug Combination (12) · Buprenorphine (11) · Sublocade (7) · Methadone (5) · Naloxone (3) · Fentanyl (2) · Morphine (2) · Oxycodone (2) · 2-Propanol (1) · Bupivacaine (1) · Control Groups (1) · Decision Support Techniques (1) · Dosage Forms (1) · Hydromorphone (1) · Illicit Drugs (1)
NYU Langone Health (3) · Pouya Azar (3) · Yale University (3) · University of Alabama at Birmingham (2) · Bicycle Health (1) · Didier Jutras Aswad (1) · Duke University (1) · Erin Winstanley (1) · Friends Research Institute, Inc. (1) · Gabriel John Culbert (1) · Indivior Inc. (1) · Jenna-Leigh Wilson (1) · Lifespan (1) · Montefiore Medical Center (1) · Nova Scotia Health Authority (1)
United States (26) · Canada (6)
David Farabee, PhD (2) · Li Li, MD;PhD (2) · Pouya Azar, MD (2) · Amr Alsabbagh, DDS (1) · Amy Penwarden, MD (1) · Benjamin T Hayes, MD, MS, MPH (1) · Bernard LeFoll, PhD (1) · Cameron Wild, PhD (1) · Carolina Price, MPA (1) · Charles P O'Brien, MD, PhD (1) · David Fiellin, MD (1) · Didier Jutras Aswad, MD (1) · Erin L Winstanley, PhD (1) · Evan Wood, MD (1)
PMID 27521809, PMID 29150198, PMID 29627621, PMID 33771287, PMID 34075644, PMID 34170188, PMID 34338389, PMID 35452194, PMID 35452195, PMID 35605529, PMID 35702828, PMID 36037586, PMID 36063082, PMID 36519188, PMID 37003540, PMID 37399447, PMID 37697811, PMID 37712113, PMID 38506171, PMID 38580298, PMID 38616571, PMID 38721650, PMID 38907678, PMID 39543001, PMID 39825419, PMID 39923043, PMID 40342086, PMID 40643356, PMID 40645369, PMID 40731024, PMID 40874578, PMID 41567709
5UG1DA015831-21 (1), K23DA055695 (1), K23DA055933 (1), K23DA060329 (1), R01DA050334 (1), R01DA057342 (1), R33DA062351 (1), R61DA060583 (1), R61DA062351 (1), RM1DA055311 (1), UG1DA013035 (1)